The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1305
February 9, 2009
View Complete Issue         Table of Contents 2019 
Two New Drugs for Chronic ITP
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Two New Drugs for Chronic ITP
February 9, 2009 (Issue: 1305)
Romiplostim (Nplate - Amgen), a recombinant fusion protein injected subcutaneously, and eltrombopag (Promacta - GlaxoSmithKline), a non-peptide taken orally, have been approved by the FDA for treatment of chronic immune thrombocytopenic purpura (ITP)...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Two New Drugs for Chronic ITP
Article code: 1305b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.